Asymptomatic TB With Innovative Modified Short-course Regimens

Inclusion Criteria:

• 1. Age between 14 to 80 years;
• 2. Male or female;
• 3. Willing to provide signed informed consent, or parental consent and participantassent;
• 4. Individuals with respiratory tract specimen (including sputum/bronchoalveolarlavage fluid/lung tissue) positive for acid-fast bacilli smear/culture/molecularamplification for M. tuberculosis;
• 5. No unexplained TB-suggestive symptoms in the three months prior to screening,including cough lasting more than two weeks, night sweats, fever or weight loss;
• 6. If non-menopausal woman, agree to use or have used effective contraception duringtreatment.

Exclusion Criteria:

• 1. Combined extrapulmonary tuberculosis;
• 2. Induviduals with extensive lesion (lesion involvement exceeding 50% or theaggregate diameter of all cavities exceeding 6 cm) ;
• 3. Individuals will be excluded from enrollment if, at the time of enrollment, theirM. tuberculosis isolate is already known to be resistant to any one or more of thefollowing: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones;
• 4. Individuals with impaired liver function (alanine transaminase [ALT] or totalbilirubin [TBIL] more than 2.5 times the upper limit of normal) or combined withliver cirrhosis;
• 5. Hemoglobin is less than 70g/L, or platelet is less than 50*10^9/L;
• 6. Estimated Glomerular Filtration Rate (eGFR) is less than 30 mL/min/1.73m2;
• 7. Known allergic or intolerant to any of the study drugs;
• 8. Pregnant or breast-feeding;
• 9. Prior anti-TB treatment for more than one week in the past six months;

• 10.Known history of epilepsy, uncontrolled diabetes;

• 11.For HIV-positive subjects, T-lymphocyte (CD4 cell) counts less than 100cells/mm3;

• 12. Unable to tolerant oral treatment.